The legislation would also force companies to announce planned price hikes.
Although Berstein analyst Tim Anderson has an 'Outperfrom' rating and $88 price target on Eli Lilly, he warned clients in a note today that investors may be overlooking risks.
While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.